Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
21 Octobre 2024 - 9:58PM
Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq:
TVGN), a clinical-stage specialty immunotherapy biotech developing
off-the-shelf, genetically unmodified T cell therapeutics to treat
infectious disease and cancers, today announced its top-line
revenue forecast for its specialty care pipeline, projecting nearly
$1 billion in revenue in its launch year and a cumulative 5-year
estimate of between $18 billion and $22 billion. This forecast
reflects the company’s unique, faster, and cost-efficient drug
development model which has the potential to serve as a blueprint
to ensure sustainable medical innovation for years to come.
Pipeline
- TVGN 489:
- Treatment of SARS-CoV-2 infection in
patients with B cell hematologic cancer [part of Tevogen Bio
Oncology forecast]
- Treatment of SARS-CoV-2 infection in
patients with other cancers [part of Tevogen Bio Oncology
forecast]
- SARS-CoV-2 infection in patients
under treatment for rheumatoid arthritis
- SARS-CoV-2 infection in patients
under treatment for and psoriatic arthritis
- Treatment of Long COVID [part of
Tevogen Bio Specialty Care forecast]
- TVGN 920: Cervical cancer
prevention
- TVGN 930: EBV-associated
lymphomas
- TVGN 960: Mouth and throat
cancer
- TVGN 601: Multiple sclerosis
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company
harnessing CD8+ cytotoxic T lymphocytes, to develop off-the-shelf,
genetically unmodified T cell therapeutics to treat infectious
disease and cancers, aiming to address the significant unmet needs
of large patient populations. Tevogen leadership believes that
sustainability and commercial success in the current era of
healthcare rely on ensuring patient accessibility through advanced
science and innovative business models. Tevogen has reported
positive safety data from its proof-of-concept clinical trial, and
its key intellectual property assets are wholly owned by the
company, not subject to any third-party licensing agreements. These
assets include three granted patents and numerous pending patents,
two of which are related to artificial intelligence.
Tevogen is driven by a team of experienced industry leaders and
scientists with drug development and global product launch
experience. Tevogen’s leadership believes that accessible
personalized therapeutics are the next frontier of medicine, and
that disruptive business models are required to sustain medical
innovation.
Forward Looking Statements
This press release contains certain forward-looking statements,
including without limitation statements relating to: expectations
regarding the healthcare and biopharmaceutical industries;
Tevogen’s development of, the potential benefits of, and patient
access to its product candidates for the treatment of infectious
diseases, cancer and neurological disorders, including TVGN 489 for
the treatment of COVID-19 and Long COVID; Tevogen’s ability to
develop additional product candidates, including through use of
Tevogen’s ExacTcell platform; the anticipated benefits of
ExacTcell; expectations regarding Tevogen’s future clinical trials;
and Tevogen’s ability to generate revenue in the future.
Forward-looking statements can sometimes be identified by words
such as “may,” “could,” “would,” “expect,” “anticipate,”
“possible,” “potential,” “goal,” “opportunity,” “project,”
“believe,” “future,” and similar words and expressions or their
opposites. These statements are based on management’s expectations,
assumptions, estimates, projections and beliefs as of the date of
this press release and are subject to a number of factors that
involve known and unknown risks, delays, uncertainties and other
factors not under the company’s control that may cause actual
results, performance or achievements of the company to be
materially different from the results, performance or other
expectations expressed or implied by these forward-looking
statements.
Factors that could cause actual results, performance, or
achievements to differ from those expressed or implied by
forward-looking statements include, but are not limited to: that
Tevogen will need to raise additional capital to execute its
business plan, which may not be available on acceptable terms or at
all; the effect of the recent business combination with Semper
Paratus Acquisition Corporation (the “Business Combination”) on
Tevogen’s business relationships, operating results, and business
generally; the outcome of any legal proceedings that may be
instituted against Tevogen; changes in the markets in which Tevogen
competes, including with respect to its competitive landscape,
technology evolution, or regulatory changes; changes in domestic
and global general economic conditions; the risk that Tevogen may
not be able to execute its growth strategies or may experience
difficulties in managing its growth and expanding operations; the
risk that Tevogen may not be able to develop and maintain effective
internal controls; costs related to the Business Combination and
the failure to realize anticipated benefits of the Business
Combination; the failure to achieve Tevogen’s commercialization and
development plans and identify and realize additional
opportunities, which may be affected by, among other things,
competition, the ability of Tevogen to grow and manage growth
economically and hire and retain key employees; the risk that
Tevogen may fail to keep pace with rapid technological developments
to provide new and innovative products and services or make
substantial investments in unsuccessful new products and services;
the ability to develop, license or acquire new therapeutics; that
Tevogen will need to raise additional capital to execute its
business plan, which may not be available on acceptable terms or at
all; the risk of regulatory lawsuits or proceedings relating to
Tevogen’s business; uncertainties inherent in the execution, cost,
and completion of preclinical studies and clinical trials; risks
related to regulatory review, approval and commercial development;
risks associated with intellectual property protection; Tevogen’s
limited operating history; and those factors discussed or
incorporated by reference in Tevogen’s Annual Report on Form 10-K
and subsequent filings with the SEC.
You should not place undue reliance on forward-looking
statements, which speak only as of the date they are made. Tevogen
undertakes no obligation to update any forward-looking statements,
except as required by applicable law.
Contacts
Tevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
Tevogen Bio (NASDAQ:TVGN)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Tevogen Bio (NASDAQ:TVGN)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024